Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities

Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

News Summary

- Solvias, one of the world’s leading independent pharmaceutical testing and manufacturing companies, has acquired Netherlands-based Cergentis to bolster its biologics and cell & gene therapy testing capabilities.

- With global sales of cell & gene therapies projected to accelerate at a 63% compound annual growth rate, more researchers require sophisticated solutions to validate the safety & efficacy of these advanced new therapies.

- Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.